Head-to-Head Trial in Relapsing MS - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Head-to-Head Trial in Relapsing MS

The phase 3 OVERLORD-MS trial compared 2 anti-CD20 therapies in previously untreated adults with newly diagnosed relapsing multiple sclerosis and recent inflammatory disease activity.

  • By

  • Kathryn Wighton

  • July 7, 2026

  • 6 min

Share

Clinical Report: Head-to-Head Trial in Relapsing MS

Overview

The OVERLORD-MS trial demonstrated that rituximab is noninferior to ocrelizumab in preventing new or enlarging MRI lesions in patients with newly diagnosed relapsing multiple sclerosis.

Background

Relapsing multiple sclerosis (MS) is characterized by episodes of neurological dysfunction due to inflammatory demyelination. The comparison of therapies like rituximab and ocrelizumab was evaluated in the OVERLORD-MS trial.

Data Highlights

OutcomeRituximabOcrelizumab
No new/enlarging lesions (months 6-24)89%93%
Annualized relapse rate0.090.04
Confirmed disability progression at month 243%7%
Infections82%69%
Serious adverse events8%7%

Key Findings

  • Rituximab showed a noninferior efficacy compared to ocrelizumab in preventing new or enlarging MRI lesions.
  • 89% of rituximab patients and 93% of ocrelizumab patients had no new or enlarging lesions from month 6 to month 24.
  • Infections were reported in 82% of patients receiving rituximab versus 69% for ocrelizumab.
  • Serious adverse events occurred at similar rates (8% for rituximab vs 7% for ocrelizumab).
  • The estimated annualized relapse rate was 0.09 for rituximab and 0.04 for ocrelizumab.

Clinical Implications

Clinicians should consider the findings of the OVERLORD-MS trial when evaluating treatment options for newly diagnosed relapsing MS patients.

Conclusion

The OVERLORD-MS trial evaluated the comparative efficacy and safety of rituximab and ocrelizumab in relapsing MS.

Related Resources & Content

  1. Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis - PubMed
  2. the medicine maker — Oral BTK Inhibitor Shows Disability Benefit in Progressive Multiple Sclerosis Trial
  3. Brain — Evaluating the Efficacy of Immune Reconstitution Therapies in Multiple Sclerosis: A Comparative Analysis
  4. European Radiology — Longitudinal Analysis of T1 Brain Mapping in Early Relapsing-Remitting Multiple Sclerosis: Variability in Lesion Characteristics and Associated Disability
  5. Drugs - Real World Outcomes — Analysis of Treatment Trends, Relapse Rates, Resource Utilization, and Costs in Multiple Sclerosis Patients Transitioning to Second-Line Disease-Modifying Therapies: A Retrospective Claims Study
  6. Oral BTK Inhibitor Shows Disability Benefit in Progressive Multiple Sclerosis Trial
  7. Evaluating the Efficacy of Immune Reconstitution Therapies in Multiple Sclerosis: A Comparative Analysis
  8. Longitudinal Analysis of T1 Brain Mapping in Early Relapsing-Remitting Multiple Sclerosis: Variability in Lesion Characteristics and Associated Disability
  9. The use of high-efficacy disease-modifying therapies in multiple sclerosis: recommendations from an expert Delphi consensus | Journal of Neurology | Springer Nature Link
  10. Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis - PubMed
  11. Comparative Effectiveness and Safety of Rituximab Versus Ocrelizumab in Relapsing–Remitting Multiple Sclerosis: A Finnish Population‐Based Matched Cohort Study - PMC

Original Source(s)

Head-to-Head Trial in Relapsing MS

  • by Kathryn Wighton

  • July 7, 2026

Related Content

FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI

The macrocyclic gadolinium-based contrast agent has a recommended dose of 0.01 mmol/kg actual body weight.

In Memoriam: J. Richard Baringer, MD (1935–2025)

Oral BTK Inhibitor Shows Disability Benefit in Progressive Multiple Sclerosis Trial

Phase 3 results show fenebrutinib matched OCREVUS on disability progression in PPMS

  • February 17, 2026

  • 3 min